Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9933452 | 0.92 | SIRT2 (0.52) | TLR2KMT2AMDM2SIRT2TLR1 | |
| SCHEMBL14433000 | 0.85 | TLR2 (0.59) | TLR2KMT2AMDM2TLR1MDM4 | |
| SCHEMBL21326214 | 0.85 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 | |
| SCHEMBL21326215 | 0.85 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 | |
| SCHEMBL17747061 | 0.85 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 | |
| SCHEMBL17747033 | 0.85 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 | |
| SCHEMBL17747040 | 0.85 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 | |
| SCHEMBL21908195 | 0.85 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 | |
| SCHEMBL14877938 | 0.85 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 | |
| SCHEMBL17747043 | 0.85 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796756-B2 | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3192800-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2652134-B1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | ARROWHEAD PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20160102120-A1 | Galactose Cluster-Pharmacokinetic Modulator Targeting Moiety for siRNA | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2016-04-14 | — | — | US | disclosed |
| US-9249179-B2 | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA | Arrowhead Madison Inc. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2652134-A2 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | Arrowhead Research Corporation (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | ARROWHEAD RESEARCH CORPORATION | 2012-06-21 | — | — | US | disclosed |
| WO-2012083046-A2 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | ARROWHEAD RESEARCH CORPORATION (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102120-A1 | Galactose Cluster-Pharmacokinetic Modulator Targeting Moiety for siRNA | GALK1, GALE, GALNT6 | TLR2 2730/4885KMT2A 1963/4885MDM2 2432/4885 |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | GALK1, GALE, GALNT6 | TLR2 2730/4885KMT2A 1963/4885MDM2 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.